☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Conquer
Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III CONQUER Study for Chronic and Episodic Migraine
August 5, 2019
Load more...
Back to Home